Dr Reddy’s shares gain after Canada nod for semaglutide; marking first G7 approval
Shares of Dr. Reddy’s Laboratories Ltd. opened higher on Thursday, April 29, after the company received approval from Health Canada for its semaglutide product. The approval makes Canada the first G7 market to clear a generic version of Semaglutide, with the company receiving a Drug Identification Number on April 22, 2026, in line with its…
